Inari Medical to Present in Upcoming Investor Conferences
Inari Medical, Inc. (NASDAQ: NARI) announced its participation in two upcoming investor conferences. The BTIG Virtual MedTech Conference will take place on February 17, 2021, at 4:00 p.m. ET, while the SVB Leerink Partners Virtual Global Healthcare Conference is scheduled for February 24, 2021, at 1:00 p.m. ET. Both presentations will be available for live streaming on the company’s Investor Relations webpage. Inari specializes in medical devices for venous disease treatment, with products like the ClotTriever and FlowTriever systems designed for thrombectomy.
- None.
- None.
IRVINE, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the following upcoming investor conferences:
- The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, Wednesday, February 17, 2021 at 4:00 p.m. Eastern Time
- The 2021 SVB Leerink Partners Virtual Global Healthcare Conference, Wednesday, February 24, 2021 at 1:00 p.m. Eastern Time. A live webcast of the presentation may be accessed on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.
About Inari Medical, Inc.
Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium.
Investor Contact:
Westwicke Partners
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
FAQ
What is the schedule for Inari Medical's upcoming investor conferences?
Where can I watch Inari Medical's conference presentations?
What products does Inari Medical offer for venous disease?
Is Inari Medical a publicly traded company?
